27 Acinetobacter

https://www.cdc.gov/hai/organisms/acinetobacter.html

25 cases

8 deaths

68 % of cases were hospitalized

2.1 cases per 100,000 population


27.1 Epidemiologic Review

27.1.1 Disease Information

Overview: Carbapenem-resistant Acinetobacter is a bacterium that is resistant to one or more carbapenem antibiotics. Carbapenemase-producing bacteria make enzymes called carbapenemases that inactivate carbapenems and other β-lactam antibiotics, including penicillins and cephalosporins. The five most common carbapenemases are KPC, NDM, VIM, OXA, and IMP.

Symptoms: Symptoms vary depending on the type of disease and some people may be asymptomatic.

Transmission: The pathogen is transmitted person-to-person or contact with a contaminated surface or medical equipment.

Treatment: Treatment varies with each isolate. Some cases may be susceptible to a small number of antibiotics while others are pan-resistant, meaning no treatment is available.

Prevention Proper hand hygiene, use of personal protective equipment and environmental cleaning practices help reduce the spread of disease. Practicing antibiotic stewardship could help in reducing antibiotic resistance.

27.1.2 Demographics


Rates for <1, 1-4, 5-17, and 18-29 years of age are not displayed due low case counts.

Racial demographic data are not presented due to low counts.


Ethnicity Rate per 100k
Hispanic or Latino 2.1
Not Hispanic or Latino 2.2


Rates for Unknown Ethnicity are not displayed due to low case counts.

27.1.3 Outbreaks

2 cases were part of an OXA-23 outbreak at a care center that started in 2021.

27.1.4 Monthly and Historical Comparisons



Data for Utah and the CDC were retrieved from the CDC’s Notifiable Infectious Disease Data Tables and were available up until 2020. National data was not available for this disease in the time range at time of report.

27.2 Key Things to Know

  • Common comorbidities among cases included diabetes and obesity.
  • 33% of cases had a risk factor of non-healing wounds.
  • Of the cases who were hospitalized, 55% had a stay in an intensive care unit.
  • 96% of isolates were resistant to meropenem.
  • 10 cases were carbapenemase producers: 5 OXA-23 and 5 OXA-235.